A radioligand is a radioactive biochemical substance, in particular, a ligand that is radiolabeled. Radioligands are used for diagnosis or for research-oriented study of the receptor systems of the body, and for anti-cancer radioligand therapy.

In a neuroimaging application the radioligand is injected into the pertinent tissue, or infused into the bloodstream. It binds to its receptor. When the radioactive isotope in the ligand decays it can be measured by positron emission tomography (PET) or single-photon emission computed tomography (SPECT). In in vivo systems it is often used to quantify the binding of a test molecule to the binding site of a radioligand. The higher the affinity of the molecule the more radioligand is displaced from the binding site and the increasing radioactive decay can be measured by scintillography. This assay is commonly used to calculate the binding constant of molecules to receptors.

The transport of the radioligand is described by receptor kinetics.

History

Radioligands are credited with making possible the study of biomolecular behaviour, a previously mysterious area of research that had evaded researchers.[1] With this capacity radioligand techniques enabled researchers to identify receptor devices within cells.

Radioactive isotopes commonly used

In PET the isotopes fluorine-18, carbon-11, and copper-64 are often used in molecular imaging.

List of radioligands

Radioligands may be constructed to bind selectively to a particular neuroreceptor or a particular neurotransmitter transporter. Examples of radioligands include:

See also

References

  1. ↑ Niehoff, Debra (2005). The Language of Life: How cells communicate in life & disease. Joseph Henry Press. ISBN 0-309-08989-1.
  2. ↑ Wong, Dean F.; Lever, John R.; Hartig, Paul R.; Dannals, Robert F.; Villemagne, Victor; Hoffman, Beth J.; Wilson, Alan A.; Ravert, Hayden T.; Links, Jonathan M. (1987). "Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-bromo-LSD". Synapse. 1 (5): 393–398. doi:10.1002/syn.890010502. PMID 2905532. S2CID 29487429.
  3. ↑ Karen H. Adams, Lars H. Pinborg, Claus Svarer, S. G. Hasselbalch, Søren Holm, Steven Haugbøl, K. Madsen, Vibe G. Frøkjær, L. Martiny Olaf B. Paulson, Gitte Moos Knudsen (March 2004). "A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables". NeuroImage. 21 (3): 1105–1113. doi:10.1016/j.neuroimage.2003.10.046. ISSN 1053-8119. PMID 15006678. S2CID 24403109.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ J. C. Baron; Y. Samson; D. Comar; C. Crouzel; P. Deniker; Y. Agid (1985). "Etude in vivo des recepteurs serotoninergiques centraux chez l'homme par tomographie a positions. [In vivo study of central serotoninergic receptors in man using positron tomography]". Revue neurologique (in French). 141 (8–9): 537–545. PMID 2935920.
  5. ↑ Reimold M, Smolka MN, Zimmer A, et al. (2007). "Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study". J Neural Transm. 114 (12): 1603–9. doi:10.1007/s00702-007-0785-6. PMID 17713719. S2CID 33872765.
  6. ↑ Pertwee RG (1999). "Pharmacology of cannabinoid receptor ligands". Curr. Med. Chem. 6 (8): 635–64. doi:10.2174/0929867306666220401124036. PMID 10469884. S2CID 247897453.
  7. ↑ Alexander Hammers, Matthias J. Koepp, Mark P. Richardson, Rene Hurlemann, David J. Brooks & John S. Duncan (June 2003). "Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients". Brain. 126 (Pt 6): 1300–1308. doi:10.1093/brain/awg138. PMID 12764053.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ↑ Seeman P, Ulpian C, Larsen RD, Anderson PS (August 1993). "Dopamine receptors labelled by PHNO". Synapse. 14 (4): 254–262. doi:10.1002/syn.890140403. PMID 7902615. S2CID 24111743.
  9. ↑ Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM. (March 2002). "Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications". Synapse. 43 (3): 181–187. doi:10.1002/syn.10038. PMID 11793423. S2CID 28591014.

Further reading

  • John Charles Matthews (1993). Fundamentals of Receptor, Enzyme, and Transport Kinetics. CRC Press. ISBN 0-8493-4426-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.